Ubrogepant
Calcitonin Gene-Related Peptide (Cgrp) Antagonists
Sold as UBRELVY
- Drug class
- Calcitonin Gene-Related Peptide (Cgrp) Antagonists
- Availability
- See label
- Routes
- Oral
- Markets covered
- 1
- Products on record
- 2
Overview
Ubrogepant is an active pharmaceutical ingredient in the Calcitonin Gene-Related Peptide (Cgrp) Antagonists group (N02CD). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 2 | September 19, 2025 |
CACanada· Health Canada
2 products
2 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [1].
Brands in Canada (1)
Drug interactions
Known interactions involving Ubrogepant. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 02532530 · revised September 19, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.